LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Other EventsItem 8.01Other Information.
On November 10, 2017, Ligand signed a License Agreement and a Supply Agreement via a subsidiary with Meridian Laboratories Inc. granting Meridian an exclusive right to use Captisol® in Meridian’s development and commercialization of a Captisol®-enabled version of a specified compound. Under the License Agreement, Ligand could potentially receive payments associated with certain licenses, royalties and milestone payments. And, Ligand could receive commercial revenue from the shipment of Captisol to Meridian for clinical and commercial activities.
Captisol® is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
About LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.